Evidence map›Paper›PMID 19132189›Full record

ArticleThrombosis and haemostasis2009

Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C.

Subramanian Yegneswaran, Phuong M Nguyen, Andrew J Gale, John H Griffin

Open access · greenAbstract read
In one paragraph

Article in Thrombosis and haemostasis, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Factor V variants in bleeding and thrombosis.Research and practice in thrombosis and haemostasis · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Subramanian YegneswaranDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, 10550, North Torrey Pines Road, MEM180, La Jolla, CA, 92037, USA.
Phuong M Nguyen
Andrew J Gale
John H Griffin
Scripps Research Institute · US

Funding

Structure and Function of Protein CR01HL052246 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI GRIFFIN, JOHN H · 2005 to 2017
$9.6M
PROTEINS OF COAGULATION PATHWAYSR01HL021544 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI GRIFFIN, JOHN H · 1985 to 2014
$7.5M
STRUCTURE/FUNCTION OF PROTEIN CR37HL052246 · NHLBI · SCRIPPS RESEARCH INSTITUTE · PI GRIFFIN, JOHN H · 1995 to 2004
$2.9M
Stabilized factor VIIIa as therapy for hemophilia AR01HL082588 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI GALE, ANDREW J · 2005 to 2008
$1.4M
NHLBI NIH HHS R01 HL021544NHLBI NIH HHS R01 HL052246NHLBI NIH HHS R01 HL082588NHLBI NIH HHS R37 HL052246
6 · The paper itself

Abstract

The hypothesis that prothrombin (FII) protects coagulation factor Va (FVa) from proteolytic inactivation by activated protein C (APC) was tested using purified proteins. FII dose-dependently protected FVa from APC proteolysis under conditions where competition of proteins for binding to negatively-charged phospholipid surface was not relevant (i.e. either at high phospholipid vesicle concentrations or using soluble dicaproylphosphatidylserine at levels below its critical micellar concentration). Cleavages in FVa at both Arg(506) and Arg(306) by APC were inhibited by FII. FII did not alter the amidolytic activity of APC towards chromogenic oligopeptide substrates or inhibit FVIIIa inactivation by APC, implying that the FII-mediated protection of FVa from APC proteolysis was due to the ability of FII to inhibit protein-protein interactions between FVa and APC. FII also protected FVa from inactivation by Gla-domainless APC, ruling out a role for the APC Gla domain for these observations. To identify domains of FII responsible for the observed phenomenon, various forms or fragments of FII were employed. Biotin-Phe-ProArg-CMK-inhibited meizothrombin and fII-fragment 1*2 protected FVa from proteolysis by APC. In contrast, no significant protection of FVa from APC cleavage was observed for Gladomainless-FII, prethrombin-1, prethrombin-2, FII fragment 1 or active site inhibited-thrombin (DEGR-thrombin). Overall, these data demonstrate that the Gla domain of FII linked to kringle 1 and 2 is necessary for the ability of FII to protect FVa from APC cleavage and support the general concept that assembly of the FII activation complex (FXa*FVa*FII*lipid surface) protects FVa from APC inactivation so that the procoagulant, thrombin generating pathway can act unhindered by APC. Only following FII activation and dissociation of the FII Gla domain fragments from the FII-ase complex, can APC inactivate FVa and down-regulate thrombin generation.

Indexed as

Blood CoagulationAnimalsBinding, CompetitiveEnzyme PrecursorsFactor VaFactor VIIIaFactor XaHumansKringlesMutationPeptide FragmentsPhospholipidsProtein BindingProtein CProtein Structure, TertiaryProthrombinEnzyme PrecursorsFactor VaFactor VIIIaFactor XameizothrombinPeptide FragmentsPhospholipidsprethrombinsProtein CProthrombinprothrombin fragment 1.2Recombinant ProteinsThrombin

Identifiers

PMID19132189
PMCPMC2730196
OpenAlexW2055883779

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.